Frederic H. Moll
Frederic H. Moll's purchase track record
How the stock did after each of Frederic H. Moll's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/6/2026 | SSII | $2.00M | -14.9% | -23.2% | +14.5% |
| 8/13/2025 | PRCT | $785K | -23.8% | -29.4% | +7.3% |
| 2/20/2025 | SSII | $5.00M | -10.0% | -24.6% | +4.1% |
| 1/9/2025 | SSII | $2.00M | +10.1% | -33.9% | +7.8% |
| 12/31/2024 | SSII | $3.00M | +23.6% | -28.3% | +5.4% |
| 11/25/2024 | SSII | $5.00M | +162.2% | +91.3% | -1.1% |
| 9/17/2021 | PRCT | $10.00M | -36.4% | -17.5% | +0.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
SSII Submits FDA Response for SSi Mantra Robotic System. SS Innovations International has submitted a response to the FDA regarding its 510(k) submission for the SSi Mantra surgical robotic system. This regulatory update addresses a request for additional information, marking a step in the approval process for the company's key product. Separately, Zacks initiated coverage of the stock with a neutral recommendation.
Transaction History
| PRCT | ▲ Buy | Grant | 3,315 | $0 | 6/9/2026 | View on chart |
| SSII | ▲ Buy | Open Market | 501,253 | $2.0M | 3/6/2026 | View on chart |
| PRCT | ▲ Buy | Open Market | 20,000 | $785K | 8/13/2025 | View on chart |
| PRCT | ▲ Buy | Grant | 1,538 | $0 | 6/10/2025 | View on chart |
| SSII | ▲ Buy | Open Market | 3,645,224 | $5.0M | 2/20/2025 | View on chart |
| PRCT | ▲ Buy | Option Exercise | 5,263 | $5K | 2/10/2025 | View on chart |
| PRCT | ▲ Buy | Option Exercise | 26,749 | $36K | 2/10/2025 | View on chart |
| SSII | ▲ Buy | Open Market | 1,457,726 | $2.0M | 1/9/2025 | View on chart |
| SSII | ▲ Buy | Open Market | 2,186,589 | $3.0M | 12/31/2024 | View on chart |
| SSII | ▲ Buy | Open Market | 3,644,315 | $5.0M | 11/25/2024 | View on chart |
| PRCT | ▲ Buy | Grant | 1,376 | $0 | 6/4/2024 | View on chart |
| PRCT | ▼ Sell | Open Market | 27,242 | $1.1M | 12/6/2023 | View on chart |
| PRCT | ▼ Sell | Open Market | 51,758 | $2.0M | 12/6/2023 | View on chart |
| PRCT | ▲ Buy | Grant | 2,711 | $0 | 6/15/2023 | View on chart |
| PRCT | ▲ Buy | Grant | 2,001 | $75K | 6/7/2022 | View on chart |
| PRCT | ▼ Sell | Other | 329,890 | — | 9/17/2021 | View on chart |
| PRCT | ▲ Buy | Open Market | 400,000 | $10.0M | 9/17/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
THINK Surgical Names Rick McDowell VP of Sales
THINK Surgical, a subsidiary of PROCEPT BioRobotics, has appointed Rick McDowell as Vice President of Sales. This leadership addition is intended to support the company's commercial operations. The stock is currently trading near its 52-week low, with an average analyst target of $21.64.
THINK Surgical Names Rick McDowell VP of Sales. THINK Surgical, a subsidiary of PROCEPT BioRobotics, has appointed Rick McDowell as Vice President of Sales. This leadership addition is intended to support the company's commercial operations. The stock is currently trading near its 52-week low, with an average analyst target of $21.64.